The Role of Type 2 Diabetes Mellitus–Related Risk Factors and Drugs in Hepatocellular Carcinoma

References

• Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J. 2022;135(5):584–590. doi:10.1097/CM9.0000000000002108
   PubMed Web of Science ®Google Scholar
• Zou H, Li M, Lei Q, et al. Economic burden and quality of life of hepatocellular carcinoma in greater China: a systematic review. Front Public Health. 2022;10:801981. doi:10.3389/fpubh.2022.801981
   PubMed Web of Science ®Google Scholar
• Chen R, Li Q, Xu S, et al. Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironment. Cancer Cell Int. 2022;22(1):73. doi:10.1186/s12935-021-02435-4
   PubMed Web of Science ®Google Scholar
• Uuh-Narvaez JJ, Segura-Campos MR. Cabbage (Brassica oleracea var. capitata): a food with functional properties aimed to type 2 diabetes prevention and management. J Food Sci. 2021;86(11):4775–4798. doi:10.1111/1750-3841.15939
   PubMed Web of Science ®Google Scholar
• Mrzljak A, Cigrovski Berković M, Giovanardi F, Lai Q. The prognostic role of diabetes mellitus type 2 in the setting of hepatocellular carcinoma: a systematic review and meta-analysis. Croat Med J. 2022;63(2):176–186. doi:10.3325/cmj.2022.63.176
   PubMed Web of Science ®Google Scholar
• Tateishi R, Matsumura T, Okanoue T, et al. Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan. J Gastroenterol. 2021;56(3):261–273. doi:10.1007/s00535-020-01754-z
   PubMed Web of Science ®Google Scholar
• Zheng Z, Zhang C, Yan J, et al. Diabetes mellitus is associated with hepatocellular carcinoma: a retrospective case-control study in hepatitis endemic area. PLoS One. 2013;8(12):e84776. doi:10.1371/journal.pone.0084776
   PubMed Web of Science ®Google Scholar
• McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology. 2021;73(Suppl 1):4–13. doi:10.1002/hep.31288
   PubMed Web of Science ®Google Scholar
• Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas. Diabet Res Clin Pract. 2019;157:107843. doi:10.1016/j.diabres.2019.107843
   PubMed Web of Science ®Google Scholar
• Ohkuma T, Peters SAE, Woodward M. Sex differences in the association between diabetes and cancer: a systematic review and meta-analysis of 121 cohorts including 20 million individuals and one million events. Diabetologia. 2018;61(10):2140–2154. doi:10.1007/s00125-018-4664-5
   PubMed Web of Science ®Google Scholar
• Pang Y, Kartsonaki C, Turnbull I, et al. Diabetes, plasma glucose, and incidence of fatty liver, cirrhosis, and liver cancer: a prospective study of 0.5 million people. Hepatology. 2018;68(4):1308–1318. doi:10.1002/hep.30083
   PubMed Web of Science ®Google Scholar
• Wang C, Wang X, Gong G, et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int, J, Cancer. 2012;130(7):1639–1648. doi:10.1002/ijc.26165
   PubMed Web of Science ®Google Scholar
• Wang P, Kang D, Cao W, Wang Y, Liu Z. Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2012;28(2):109–122. doi:10.1002/dmrr.1291
   PubMed Web of Science ®Google Scholar
• Koh WP, Wang R, Jin A, Yu MC, Yuan JM. Diabetes mellitus and risk of hepatocellular carcinoma: findings from the Singapore Chinese Health Study. Br J Cancer. 2013;108(5):1182–1188. doi:10.1038/bjc.2013.25
   PubMed Web of Science ®Google Scholar
• Tian Y, Yang B, Qiu W, et al. ER-residential Nogo-B accelerates NAFLD-associated HCC mediated by metabolic reprogramming of oxLDL lipophagy. Nat Commun. 2019;10(1):3391. doi:10.1038/s41467-019-11274-x
   PubMedGoogle Scholar
• Yoo -J-J, Cho EJ, Han K, et al. Glucose variability and risk of hepatocellular carcinoma in patients with diabetes: a nationwide population-based study. Cancer Epidemiol Biomarkers Prev. 2021;30(5):974–981. doi:10.1158/1055-9965.EPI-20-1654
   PubMed Web of Science ®Google Scholar
• Pfister D, Núñez NG, Pinyol R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592:7854):450–456. doi:10.1038/s41586-021-03362-0
   Web of Science ®Google Scholar
• Supabphol S, Seubwai W, Wongkham S, Saengboonmee C. High glucose: an emerging association between diabetes mellitus and cancer progression. J Mol Med. 2021;99(9):1175–1193. doi:10.1007/s00109-021-02096-w
   PubMed Web of Science ®Google Scholar
• Topel H, Bağırsakçı E, Yılmaz Y, et al. High glucose induced c-Met activation promotes aggressive phenotype and regulates expression of glucose metabolism genes in HCC cells. Sci Rep. 2021;11(1):11376. doi:10.1038/s41598-021-89765-5
   PubMed Web of Science ®Google Scholar
• Rizwan H, Pal S, Sabnam S, Pal A. High glucose augments ROS generation regulates mitochondrial dysfunction and apoptosis via stress signalling cascades in keratinocytes. Life Sci. 2020;241:117148. doi:10.1016/j.lfs.2019.117148
   PubMed Web of Science ®Google Scholar
• G Bardallo R, Panisello-Roselló A, Sanchez-Nuno S, Alva N, Roselló-Catafau J, Carbonell T. Nrf2 and oxidative stress in liver ischemia/reperfusion injury. FEBS J. 2022;289(18):5463–5479. doi:10.1111/febs.16336
   PubMed Web of Science ®Google Scholar
• Xu J, Ji L, Ruan Y, et al. UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGC1β in hepatocellular carcinoma. Signal Transduct Target Ther. 2021;6(1):190. doi:10.1038/s41392-021-00594-4
   PubMed Web of Science ®Google Scholar
• Simon J-M, Thomas F, Czernichow S, et al. Hyperglycaemia is associated with cancer-related but not non-cancer-related deaths: evidence from the IPC cohort. Diabetologia. 2018;61(5):1089–1097. doi:10.1007/s00125-017-4540-8
   PubMed Web of Science ®Google Scholar
• Ichimura-Shimizu M, Kageyama T, Oya T, et al. Verification of the impact of blood glucose level on liver carcinogenesis and the efficacy of a dietary intervention in a spontaneous metabolic syndrome model. Int J Mol Sci. 2021;22(23):12844. doi:10.3390/ijms222312844
   PubMed Web of Science ®Google Scholar
• Rachdaoui N. Insulin: the Friend and the Foe in the Development of Type 2 Diabetes Mellitus. Int J Mol Sci. 2020;21(5):1770. doi:10.3390/ijms21051770
   PubMed Web of Science ®Google Scholar
• Yang W, Sui J, Zhao L, et al. Association of Inflammatory and Insulinemic Potential of Diet and Lifestyle with Risk of Hepatocellular Carcinoma. Cancer Epidemiol Biomarkers Prev. 2021;30(4):789–796. doi:10.1158/1055-9965.EPI-20-1329
   PubMed Web of Science ®Google Scholar
• Nakatsuka T, Tateishi R. Development and prognosis of hepatocellular carcinoma in patients with diabetes. Clin Mol Hepatol. 2023;29(1):51–64. doi:10.3350/cmh.2022.0095
   PubMed Web of Science ®Google Scholar
• Mantovani A, Targher G. Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease. Ann Transl Med. 2017;5(13):270. doi:10.21037/atm.2017.04.41
   PubMed Web of Science ®Google Scholar
• Liu F, Sun Y, Liu B, et al. Insulin-like growth factor-1 induces epithelial-mesenchymal transition in hepatocellular carcinoma by activating survivin. Oncol Rep. 2018;40(2):952–958. doi:10.3892/or.2018.6516
   PubMed Web of Science ®Google Scholar
• Juratli MA, Zhou H, Oppermann E, et al. Integrin α2 and β1 cross-communication with mTOR/AKT and the CDK-cyclin axis in hepatocellular carcinoma cells. Cancers (Basel). 2022;14(10). doi:10.3390/cancers14102430
   PubMed Web of Science ®Google Scholar
• Ngo M-HT, Jeng H-Y, Kuo Y-C, et al. The Role of IGF/IGF-1R signaling in hepatocellular carcinomas: stemness-related properties and drug resistance. Int J Mol Sci. 2021;22(4):1931. doi:10.3390/ijms22041931
   PubMed Web of Science ®Google Scholar
• Huang K, Liang Y, Ma Y, Wu J, Luo H, Yi B. The variation and correlation of serum adiponectin, nesfatin-1, IL-6, and TNF-α levels in prediabetes. Front Endocrinol. 2022;13:774272. doi:10.3389/fendo.2022.774272
   PubMed Web of Science ®Google Scholar
• Zhang C, Liu S, Yang M. Hepatocellular carcinoma and obesity, type 2 diabetes mellitus, cardiovascular disease: causing factors, molecular links, and treatment options. Front Endocrinol. 2021;12:808526. doi:10.3389/fendo.2021.808526
   PubMed Web of Science ®Google Scholar
• O’Mahony G, Petersen J, Ek M, et al. Discovery by virtual screening of an inhibitor of CDK5-Mediated PPARγ phosphorylation. ACS Med Chem Lett. 2022;13(4):681–686. doi:10.1021/acsmedchemlett.1c00715
   PubMed Web of Science ®Google Scholar
• Xu J, Lin H, Wu G, Zhu M, Li M. IL-6/STAT3 is a promising therapeutic target for hepatocellular carcinoma. Front Oncol. 2021;11:760971. doi:10.3389/fonc.2021.760971
   PubMed Web of Science ®Google Scholar
• Omaru N, Watanabe T, Kamata K, Minaga K, Kudo M. Activation of NOD1 and NOD2 in the development of liver injury and cancer. Front Immunol. 2022;13:1004439. doi:10.3389/fimmu.2022.1004439
   PubMed Web of Science ®Google Scholar
• Li W, Jian Y-B. Antitumor necrosis factor-α antibodies as a novel therapy for hepatocellular carcinoma. Exp Ther Med. 2018;16(2):529–536. doi:10.3892/etm.2018.6235
   PubMed Web of Science ®Google Scholar
• Yang YM, Kim SY, Seki E. Inflammation and Liver Cancer: molecular Mechanisms and Therapeutic Targets. Semin Liver Dis. 2019;39(1):26–42. doi:10.1055/s-0038-1676806
   PubMed Web of Science ®Google Scholar
• Sun Y, Wang Q, Zhang Y, et al. Multigenerational maternal obesity increases the incidence of HCC in offspring via miR-27a-3p. J Hepatol. 2020;73(3):603–615. doi:10.1016/j.jhep.2020.03.050
   PubMed Web of Science ®Google Scholar
• Mao D, Lau ESH, Wu H, et al. Risk associations of glycemic burden and obesity with liver cancer-A 10-year analysis of 15,280 patients with type 2 diabetes. Hepatol Commun. 2022;6(6):1350–1360. doi:10.1002/hep4.1891
   PubMed Web of Science ®Google Scholar
• Hagström H, Tynelius P, Rasmussen F. High BMI in late adolescence predicts future severe liver disease and hepatocellular carcinoma: a national, population-based cohort study in 1.2 million men. Gut. 2018;67(8):1536–1542. doi:10.1136/gutjnl-2016-313622
   PubMed Web of Science ®Google Scholar
• Yang B, Petrick JL, Kelly SP, Graubard BI, Freedman ND, McGlynn KA. Adiposity across the adult life course and incidence of primary liver cancer: the NIH-AARP cohort. Int, J, Cancer. 2017;141(2):271–278. doi:10.1002/ijc.30737
   PubMed Web of Science ®Google Scholar
• Florio AA, Campbell PT, Zhang X, et al. Abdominal and gluteofemoral size and risk of liver cancer: the liver cancer pooling project. Int, J, Cancer. 2020;147(3):675–685. doi:10.1002/ijc.32760
   PubMed Web of Science ®Google Scholar
• Trojnar M, Patro-Małysza J, Kimber-Trojnar Ż, Leszczyńska-Gorzelak B, Mosiewicz J. Associations between fatty acid-binding protein 4⁻a proinflammatory adipokine and insulin resistance, gestational and type 2 diabetes mellitus. Cells. 2019;8(3):227. doi:10.3390/cells8030227
   PubMed Web of Science ®Google Scholar
• Thompson KJ, Austin RG, Nazari SS, Gersin KS, Iannitti DA, McKillop IH. Altered fatty acid-binding protein 4 (FABP4) expression and function in human and animal models of hepatocellular carcinoma. Liver Int. 2018;38(6):1074–1083. doi:10.1111/liv.13639
   PubMed Web of Science ®Google Scholar
• Yoshimoto S, Loo TM, Atarashi K, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature. 2013;499(7456):97–101. doi:10.1038/nature12347
   PubMed Web of Science ®Google Scholar
• Grohmann M, Wiede F, Dodd GT, et al. Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC. Cell. 2018;175(5):1289–1306.e20. doi:10.1016/j.cell.2018.09.053
   PubMed Web of Science ®Google Scholar
• Calzadilla Bertot L, Adams LA. The natural course of non-alcoholic fatty liver disease. Int J Mol Sci. 2016;17(5):774. doi:10.3390/ijms17050774
   PubMed Web of Science ®Google Scholar
• Tanase DM, Gosav EM, Costea CF, et al. The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and nonalcoholic fatty liver disease (NAFLD). J Diabetes Res. 2020;2020:3920196. doi:10.1155/2020/3920196
   PubMed Web of Science ®Google Scholar
• Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol. 2021;17(8):484–495. doi:10.1038/s41574-021-00507-z
   PubMed Web of Science ®Google Scholar
• Peiseler M, Schwabe R, Hampe J, Kubes P, Heikenwälder M, Tacke F. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits. J Hepatol. 2022;77(4):1136–1160. doi:10.1016/j.jhep.2022.06.012
   PubMed Web of Science ®Google Scholar
• Ponziani FR, Bhoori S, Castelli C, et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease. Hepatology. 2019;69(1):107–120. doi:10.1002/hep.30036
   PubMed Web of Science ®Google Scholar
• Koh MY, Gagea M, Sargis T, et al. A new HIF-1α/RANTES-driven pathway to hepatocellular carcinoma mediated by germline haploinsufficiency of SART1/HAF in mice. Hepatology. 2016;63(5):1576–1591. doi:10.1002/hep.28468
   PubMed Web of Science ®Google Scholar
• Tang W, Zhou J, Yang W, et al. Aberrant cholesterol metabolic signaling impairs antitumor immunosurveillance through natural killer T cell dysfunction in obese liver. Cell Mol Immunol. 2022;19(7):834–847. doi:10.1038/s41423-022-00872-3
   PubMed Web of Science ®Google Scholar
• Brown ZJ, Fu Q, Ma C, et al. Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4+ T cell apoptosis promoting HCC development. Cell Death Dis. 2018;9(6):620. doi:10.1038/s41419-018-0687-6
   PubMedGoogle Scholar
• Yang C, Huang X, Li Y, Chen J, Lv Y, Dai S. Prognosis and personalized treatment prediction in TP53-mutant hepatocellular carcinoma: an in silico strategy towards precision oncology. Brief Bioinform. 2021;22:3.
   PubMed Web of Science ®Google Scholar
• Canfora EE, Meex RCR, Venema K, Blaak EE. Gut microbial metabolites in obesity, NAFLD and T2DM. Nat Rev Endocrinol. 2019;15(5):261–273. doi:10.1038/s41574-019-0156-z
   PubMed Web of Science ®Google Scholar
• Salguero MV, Al-Obaide MAI, Singh R, Siepmann T, Vasylyeva TL. Dysbiosis of Gram-negative gut microbiota and the associated serum lipopolysaccharide exacerbates inflammation in type 2 diabetic patients with chronic kidney disease. Exp Ther Med. 2019;18(5):3461–3469. doi:10.3892/etm.2019.7943
   PubMed Web of Science ®Google Scholar
• Zhang X, Coker OO, Chu ES, et al. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. Gut. 2021;70(4):761–774. doi:10.1136/gutjnl-2019-319664
   PubMed Web of Science ®Google Scholar
• Behary J, Amorim N, Jiang X-T, et al. Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma. Nat Commun. 2021;12(1):187. doi:10.1038/s41467-020-20422-7
   PubMed Web of Science ®Google Scholar
• Wan MLY, El-Nezami H. Targeting gut microbiota in hepatocellular carcinoma: probiotics as a novel therapy. Hepatobiliary Surg Nutr. 2018;7(1):11–20. doi:10.21037/hbsn.2017.12.07
   PubMed Web of Science ®Google Scholar
• Peng L, Pan B, Zhang X, et al. Lipopolysaccharide facilitates immune escape of hepatocellular carcinoma cells via m6A modification of lncRNA MIR155HG to upregulate PD-L1 expression. Cell Biol Toxicol. 2022;38(6):1159–1173. doi:10.1007/s10565-022-09718-0
   PubMed Web of Science ®Google Scholar
• Kummer U, Zobeley J, Brasen JC, et al. Elevated glucose concentrations promote receptor-independent activation of adherent human neutrophils: an experimental and computational approach. Biophys J. 2007;92(7):2597–2607. doi:10.1529/biophysj.106.086769
   PubMed Web of Science ®Google Scholar
• Geh D, Leslie J, Rumney R, Reeves HL, Bird TG, Mann DA. Neutrophils as potential therapeutic targets in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2022;19(4):257–273. doi:10.1038/s41575-021-00568-5
   PubMed Web of Science ®Google Scholar
• Ma C, Kesarwala AH, Eggert T, et al. NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. Nature. 2016;531:7593):253–257. doi:10.1038/nature16969
   Web of Science ®Google Scholar
• Shi T, Kobara H, Oura K, Masaki T. Mechanisms underlying hepatocellular carcinoma progression in patients with type 2 diabetes. J Hepatocell Carcinoma. 2021;8:45–55. doi:10.2147/JHC.S274933
   PubMed Web of Science ®Google Scholar
• Tang L, Wang H, Cao K, et al. Dysfunction of circulating CD3+CD56+ NKT-like cells in type 2 diabetes mellitus. Int J Med Sci. 2023;20(5):652–662. doi:10.7150/ijms.83317
   PubMed Web of Science ®Google Scholar
• Koo S-Y, Park E-J, Lee C-W. Immunological distinctions between nonalcoholic steatohepatitis and hepatocellular carcinoma. Exp Mol Med. 2020;52(8):1209–1219. doi:10.1038/s12276-020-0480-3
   PubMed Web of Science ®Google Scholar
• Kramer JR, Natarajan Y, Dai J, et al. Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease. Hepatology. 2022;75(6):1420–1428. doi:10.1002/hep.32244
   PubMed Web of Science ®Google Scholar
• Tangjarusritaratorn T, Tangjittipokin W, Kunavisarut T. Incidence and survival of hepatocellular carcinoma in type 2 diabetes patients with cirrhosis who were treated with and without metformin. Diabetes Metab Syndr Obes. 2021;14:1563–1574. doi:10.2147/DMSO.S295753
   PubMed Web of Science ®Google Scholar
• Schulte L, Scheiner B, Voigtländer T, et al. Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma. Liver Int. 2019;39(4):714–726. doi:10.1111/liv.14048
   PubMed Web of Science ®Google Scholar
• Antwi SO, Li Z, Mody K, Roberts LR, Patel T. Independent and joint use of statins and metformin by elderly patients with diabetes and overall survival following HCC diagnosis. J Clin Gastroenterol. 2020;54(5):468–476. doi:10.1097/MCG.0000000000001182
   PubMed Web of Science ®Google Scholar
• Huang M-Y, Chung C-H, Chang W-K, et al. The role of thiazolidinediones in hepatocellular carcinoma risk reduction: a population-based cohort study in Taiwan. Am J Cancer Res. 2017;7(7):1606–1616.
   PubMed Web of Science ®Google Scholar
• Lai S-W, Chen P-C, Liao K-F, Muo C-H, Lin -C-C, Sung F-C. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol. 2012;107(1):46–52. doi:10.1038/ajg.2011.384
   PubMed Web of Science ®Google Scholar
• Lee J-Y, Jang S-Y, Nam CM, Kang ES. Incident hepatocellular carcinoma risk in patients treated with a sulfonylurea: a nationwide, nested, case-control study. Sci Rep. 2019;9(1):8532. doi:10.1038/s41598-019-44447-1
   PubMedGoogle Scholar
• Schlesinger S, Aleksandrova K, Pischon T, et al. Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort. Ann Oncol. 2013;24(9):2449–2455. doi:10.1093/annonc/mdt204
   PubMed Web of Science ®Google Scholar
• Nakano D, Kawaguchi T, Iwamoto H, Hayakawa M, Koga H, Torimura T. Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT). PLoS One. 2020;15(4):e0232283. doi:10.1371/journal.pone.0232283
   PubMed Web of Science ®Google Scholar
• Foretz M, Guigas B, Viollet B. Metformin: update on mechanisms of action and repurposing potential. Nat Rev Endocrinol. 2023;19(8):460–476. doi:10.1038/s41574-023-00833-4
   PubMed Web of Science ®Google Scholar
• Iranshahy M, Rezaee R, Karimi G. Hepatoprotective activity of metformin: a new mission for an old drug? Eur J Pharmacol. 2019;850:1–7. doi:10.1016/j.ejphar.2019.02.004
   PubMed Web of Science ®Google Scholar
• Miele L, Bosetti C, Turati F, et al. Diabetes and insulin therapy, but not metformin, are related to hepatocellular cancer risk. Gastroenterol Res Pract. 2015;2015:570356. doi:10.1155/2015/570356
   PubMed Web of Science ®Google Scholar
• Yuan B, Ma J, Wang J, Hao J. The effect of metformin usage on survival outcomes for hepatocellular carcinoma patients with type 2 diabetes mellitus after curative therapy. Front Endocrinol. 2022;13:1060768. doi:10.3389/fendo.2022.1060768
   PubMed Web of Science ®Google Scholar
• Jin P, Jiang J, Zhou L, et al. Disrupting metformin adaptation of liver cancer cells by targeting the TOMM34/ATP5B axis. EMBO Mol Med. 2022;14(12):e16082. doi:10.15252/emmm.202216082
   PubMed Web of Science ®Google Scholar
• Hu A, Hu Z, Ye J, et al. Metformin exerts anti-tumor effects via Sonic hedgehog signaling pathway by targeting AMPK in HepG2 cells. Biochem Cell Biol. 2022;100(2):142–151. doi:10.1139/bcb-2021-0409
   PubMedGoogle Scholar
• Tawfik SM, Abdollah MRA, Elmazar MM, El-Fawal HAN, Abdelnaser A. Effects of metformin combined with antifolates on hepG2 cell metabolism and cellular proliferation. Front Oncol. 2022;12:828988. doi:10.3389/fonc.2022.828988
   PubMed Web of Science ®Google Scholar
• Luo C, Liang J, Sharabi K, et al. Obesity/type 2 diabetes-associated liver tumors are sensitive to cyclin D1 deficiency. Cancer Res. 2020;80(16):3215–3221. doi:10.1158/0008-5472.CAN-20-0106
   PubMed Web of Science ®Google Scholar
• de Oliveira S, Houseright RA, Graves AL, et al. Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish. J Hepatol. 2019;70(4):710–721. doi:10.1016/j.jhep.2018.11.034
   PubMed Web of Science ®Google Scholar
• Wabitsch S, McCallen JD, Kamenyeva O, et al. Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD. J Hepatol. 2022;77(3):748–760. doi:10.1016/j.jhep.2022.03.010
   PubMed Web of Science ®Google Scholar
• Papadakos SP, Ferraro D, Carbone G, et al. The emerging role of metformin in the treatment of hepatocellular carcinoma: is there any value in repurposing metformin for HCC immunotherapy? Cancers (Basel). 2023;15(12):3161. doi:10.3390/cancers15123161
   PubMed Web of Science ®Google Scholar
• Yip TC-F, Wong VW-S, Chan HL-Y, et al. Thiazolidinediones reduce the risk of hepatocellular carcinoma and hepatic events in diabetic patients with chronic hepatitis B. J Viral Hepat. 2020;27(9):904–914. doi:10.1111/jvh.13307
   PubMed Web of Science ®Google Scholar
• Arvind A, Memel ZN, Philpotts LL, Zheng H, Corey KE, Simon TG. Thiazolidinediones, alpha-glucosidase inhibitors, meglitinides, sulfonylureas, and hepatocellular carcinoma risk: a meta-analysis. Metabolism. 2021;120:154780. doi:10.1016/j.metabol.2021.154780
   PubMed Web of Science ®Google Scholar
• Biondo LA, Teixeira AAS, de O S Ferreira KC, Neto JCR. Pharmacological strategies for insulin sensitivity in obesity and cancer: thiazolidinediones and metformin. Curr Pharm Des. 2020;26(9):932–945. doi:10.2174/1381612826666200122124116
   PubMed Web of Science ®Google Scholar
• Qiu -Y-Y, Zhang J, Zeng F-Y, Zhu YZ. Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD). Pharmacol Res. 2023;192:106786. doi:10.1016/j.phrs.2023.106786
   PubMed Web of Science ®Google Scholar
• Liu Y, Hu X, Shan X, Chen K, Tang H. Rosiglitazone metformin adduct inhibits hepatocellular carcinoma proliferation via activation of AMPK/p21 pathway. Cancer Cell Int. 2019;19:13. doi:10.1186/s12935-019-0732-2
   PubMed Web of Science ®Google Scholar
• Bril F, Kalavalapalli S, Clark VC, et al. Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes. Clin Gastroenterol Hepatol. 2018;16(4):558–566.e2. doi:10.1016/j.cgh.2017.12.001
   PubMed Web of Science ®Google Scholar
• Li S, Ghoshal S, Sojoodi M, et al. Pioglitazone reduces hepatocellular carcinoma development in two rodent models of cirrhosis. J Gastrointest Surg. 2019;23(1):101–111. doi:10.1007/s11605-018-4004-6
   PubMed Web of Science ®Google Scholar
• Yang Y, Zhao L-H, Huang B, et al. Pioglitazone, a PPARγ agonist, inhibits growth and invasion of human hepatocellular carcinoma via blockade of the rage signaling. Mol, Carcinog. 2015;54(12):1584–1595. doi:10.1002/mc.22231
   PubMed Web of Science ®Google Scholar
• Bosetti C, Franchi M, Nicotra F, et al. Insulin and other antidiabetic drugs and hepatocellular carcinoma risk: a nested case-control study based on Italian healthcare utilization databases. Pharmacoepidemiol Drug Saf. 2015;24(7):771–778. doi:10.1002/pds.3801
   PubMed Web of Science ®Google Scholar
• Plaz Torres MC, Jaffe A, Perry R, Marabotto E, Strazzabosco M, Giannini EG. Diabetes medications and risk of HCC. Hepatology. 2022;76(6):1880–1897. doi:10.1002/hep.32439
   PubMed Web of Science ®Google Scholar
• Lee JY, Kim G, Lee YH, et al. Comparison of hepatocellular carcinoma risk between patients treated with glimepiride and gliclazide. Diabetes Metab. 2019;45(1):83–85. doi:10.1016/j.diabet.2017.06.007
   PubMed Web of Science ®Google Scholar
• Amemiya H, Matsuda M, Saito R, et al. Impact of insulin treatment on prognosis of non-B non-C hepatocellular carcinoma after hepatectomy. Anticancer Res. 2021;41(1):317–326. doi:10.21873/anticanres.14778
   PubMed Web of Science ®Google Scholar
• Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol. 2013;108:6.
   Web of Science ®Google Scholar
• Baba H, Kurano M, Nishida T, Hatta H, Hokao R, Tsuneyama K. Facilitatory effect of insulin treatment on hepatocellular carcinoma development in diabetes. BMC Res Notes. 2017;10(1):478. doi:10.1186/s13104-017-2783-6
   PubMedGoogle Scholar
• Yan J-B, Lai -C-C, Jhu J-W, et al. Insulin and metformin control cell proliferation by regulating TDG-Mediated DNA demethylation in liver and breast cancer cells. Mol Ther Oncolytics. 2020;18:282–294. doi:10.1016/j.omto.2020.06.010
   PubMed Web of Science ®Google Scholar
• Meng Z, Liu X, Li T, et al. The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway. Int Immunopharmacol. 2021;94:107492. doi:10.1016/j.intimp.2021.107492
   PubMed Web of Science ®Google Scholar
• Nasiri-Ansari N, Nikolopoulou C, Papoutsi K, et al. Empagliflozin attenuates non-alcoholic fatty liver disease (NAFLD) in High Fat Diet Fed ApoE(-/-) Mice by activating autophagy and reducing ER stress and apoptosis. Int J Mol Sci. 2021;22(2):818. doi:10.3390/ijms22020818
   PubMed Web of Science ®Google Scholar
• Jojima T, Wakamatsu S, Kase M, et al. The SGLT2 inhibitor canagliflozin prevents carcinogenesis in a mouse model of diabetes and non-alcoholic steatohepatitis-related hepatocarcinogenesis: association with SGLT2 expression in hepatocellular carcinoma. Int J Mol Sci. 2019;20(20):5237. doi:10.3390/ijms20205237
   PubMed Web of Science ®Google Scholar
• Hendryx M, Dong Y, Ndeke JM, Luo J. Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis. PLoS One. 2022;17(9):e0274519. doi:10.1371/journal.pone.0274519
   PubMed Web of Science ®Google Scholar
• Elemeery MN, Mohamed MA, Madkour MA, et al. MicroRNA signature in patients with hepatocellular carcinoma associated with type 2 diabetes. World J Gastroenterol. 2019;25(42):6322–6341. doi:10.3748/wjg.v25.i42.6322
   PubMed Web of Science ®Google Scholar
• Liu G-M, Zeng H-D, Zhang C-Y, J-W X. Key genes associated with diabetes mellitus and hepatocellular carcinoma. Pathol Res Pract. 2019;215(11):152510. doi:10.1016/j.prp.2019.152510
   PubMed Web of Science ®Google Scholar
• Wei H, Wang J, Li W, et al. The underlying pathophysiology association between the Type 2-diabetic and hepatocellular carcinoma. J Cell Physiol. 2019;234(7):10835–10841. doi:10.1002/jcp.27919
   PubMed Web of Science ®Google Scholar
• Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019;16(7):411–428. doi:10.1038/s41575-019-0145-7
   PubMed Web of Science ®Google Scholar